Palantir is gaining significant traction in the tech world with its AI-driven services, experiencing a dramatic stock ...

Merck & Co. Inc. closed 36.37% below its 52-week high of $134.63, which the company reached on June 25th.

TD Cowen downgraded Merck (MRK) to Hold from Buy with a price target of $100, down from $121. The firm says its Buy thesis “broke down” with ...

Big Tech and pharmaceutical companies are accelerating the implementation of artificial intelligence in the healthcare ...

This $15M payment marks the second milestone achieved in the collaboration with Merck. Under the agreement, Neuphoria is eligible to receive up to $450M in additional milestone payments for certain ...

Merck KGaA, the German healthcare and technology group, is in advanced talks to acquire U.S. cancer and rare diseases ...

A transaction for Springworks would rank as one of the biggest pharma deals for Merck in recent years and boost its ongoing ...

Shares of Merck & Co. Inc. MRK slid 1.81% to $88.05 Thursday, on what proved to be an all-around mixed trading session for ...

Merck KGaA, the German healthcare and technology group, is in advanced talks to acquire U.S. cancer and rare diseases ...

Germany’s Merck KGaA is in advanced talks to aquire the U.S. biopharmaceutical company that specializes in rare diseases and cancer.

Co's stock has reached a 52-week low, dipping to $85.71. This downturn reflects a significant shift from the previous year, with the pharmaceutical giant experiencing a 1-year change of -31.59%.